TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: SISTERS: Spasticity In Stroke Study - Randomized Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~To be eligible for inclusion into this study, patients must fulfill all of the following criteria prior to study enrollment:~1. patient (or legal guardian) has been informed of the study procedures and has given written informed consent~2. patient experienced last stroke \> 6 months prior to enrollment~3. patient presents spasticity in at least 2 extremities~4. patient presents an Ashworth score ≥ 3 in a minimum of two of the affected muscle groups in the lower extremities~5. patient is eligible to receive ITB Therapy following the Adult Spasticity Algorithm. A patient does not reach his/her therapy goal with other treatment interventions~6. stable blood pressure: no change in hypertensive medication in last month (NOTE: ventriculoperitoneal shunts and valves can be present)~7. if female, she must either be post-menopausal or surgically sterilized; or use a hormonal contraceptive, intrauterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study~8. patient/family is willing to comply with study protocol including attending the study visits~Exclusion criteria:~To be eligible for inclusion in this study the patients must not meet any of the following criteria:~1. patient/family is considered by the physician to be unable or unwilling to participate in long-term ITB Therapy management~2. patient has known hypersensitivity to baclofen~3. active systemic infection (NOTE: pressure sores are not a contraindication unless they are present near the implant sites)~4. presence of a cardiac pacemaker, ICD, implantable neurostimulator or drug delivery device~5. uncontrolled refractory epilepsy~6. use of oral vitamin K antagonists, e.g. warfarin/coumadin; unless the patient can switch to another accepted anticoagulant (e.g. heparin, aggrenox, fragmin, plavix, ticlid) for the period of ITB test and implant~7. patient is pregnant or breastfeeding~8. patient received a Botulinum toxin injection less than 4 months ago

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ITB therapy (Type: ACTIVE_COMPARATOR): Intrathecal Baclofen therapy (Intrathecal baclofen + implantable pump)
- Best Medical Treatment (BMT) (Type: NO_INTERVENTION): Use one or a combination oral antispastic medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Internet-guided Cognitive Behavioural Therapy to Improve Depression Patients With Cardiovascular Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* treatment for CVD according to European Society of Cardiology guidelines.~* stable CVD (NYHA class I-III) and not having been hospitalised for CVD in in the last four weeks.~* depressive symptoms (Patient Health Questionnaire-9 17 (PHQ-9) \> 5 points)~Exclusion Criteria:~* severe CVD (NYHA IV) or another severe chronic life-threatening disease~* severe depression assessed as requiring acute treatment~* not being able to dedicate 3-4 hours to participate in the program

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Internet Cognitive Behavioural Therapy (Type: EXPERIMENTAL): Participants will perform a nine-week tailored I-CBT program developed to fit CVD patients. The program consists of psychoeducation, relaxation, problem-solving and behavioral activation.
- Moderated discussion forum (Type: PLACEBO_COMPARATOR): In this arm the participants are allocated to a non mandatory discussion forum for nine weeks. Evert week will participants discuss issues regarding their CVD. Themes discussed are suggested by the study team, and a new theme is added every week. A moderator from the study group act as a supervisor and checks that issues discussed are ok. After the nine week discussion forum the participants are offered the nine week CBT program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with a diagnosis of mild-to-moderate Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (including patients living in residential homes for the elderly or day patients)~* have a Mini-Mental Status Examination (MMSE) score of 10 - 24, and a score of at least 18 on the cognitive portion of the Alzheimer's Disease Assessment scale (ADAS-cog-11) with an onset between ages 40 and 90~* history of at least a 6 months of gradual and progressive cognitive decline~* have a consistent informant to accompany the patient on scheduled visits~Exclusion Criteria:~* Neurogenerative disorders such as Parkinson's disease~* cognitive impairment resulting from acute cerebral trauma, cerebral damage due to a lack of oxygen, vitamin deficiency, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation or a brain tumor~* dementia caused by small strokes or cerebrovascular disease~* having epilepsy, significant psychiatric disease, active peptic ulcer, clinically significant liver, kidney or lung disorders, or heart disease~* females of child bearing potential without adequate contraception

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Subjects fulfilling all of the below criteria shall be eligible for the study:~1. Patients diagnosed with gastroesophageal reflux disease who are shown through endoscopic examination to have mucosal lesions (erosions, ulcers)~2. Patients shown through endoscopy not to have recovered despite administration of PPI once daily for eight weeks.~3. Patients over 20 years of age who have freely given their informed consent in writing to participation in the study.~4. Patients who, having received a full explanation of the matters that must be adhered to during the study, intend to adhere to their requirements, and are capable of doing so.~Exclusion Criteria:~Subjects fulfilling any of the following criteria shall be excluded from the study:~1. Patients considered candidates for surgical treatment of the upper gastrointestinal tract due to perforation, esophageal stricture, pyloric stenosis, esophageal varices, etc.~2. Patients with Zollinger-Ellison syndrome.~3. Patients with gastrointestinal hemorrhage.~4. Patients with serious cardiovascular disease, cerebrovascular disease, hematological disorders, renal disease, liver disease, malignant tumors, etc.~5. Patients with long segment Barrett's esophagus.~6. Patients with open gastric or duodenal ulcers.~7. Patients with drug allergies or a past history of drug allergies to PPI.~8. Patients who are taking other drugs under development, or have done so within 12 weeks prior to enrollment.~9. Patients who are, or may be pregnant, patients who wish to become pregnant during the study period, patients who are breastfeeding, and patients or their partners who do not wish to use reliable contraceptive measures.~10. Patients with a history of dependence on or abuse of drugs or alcohol within the past two years.~11. Other patients deemed unsuitable for inclusion in the study by the principal investigator or sub-investigators.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): None
- Arm B (Type: EXPERIMENTAL): None
- Arm C (Type: EXPERIMENTAL): None
- Arm D (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Misoprostol for Second Trimester Termination of Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* gestational age between 12-24 weeks~* live fetus~* singleton pregnancy~* Bishop score \<5~* no uterine contraction~Exclusion Criteria:~* prostaglandin allergy~* a scar in uterus~* uterine abnormality~* premature rupture of membranes

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Buccal misoprostol (Type: ACTIVE_COMPARATOR): 400 µg buccal misoprostol per 3 hours
- vaginal misoprostol (Type: ACTIVE_COMPARATOR): 400 µg vaginal misoprostol per 3 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Treatment of Overactive Bladder in Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Community-dwelling~* Veteran~* Self-reported urgency~* Self-reported frequent urination~* Mean of \> 8 voids per 24-hour day on bladder diary~* Able to come to clinic~Exclusion Criteria:~* Urologic surgery in the past 6 months~* Nonambulatory (unless has independent transfer skills)~* Flow rate \< 5mL at baseline and \< 10mL/sec after run-in (on simple uroflowmetry)~* Post-void residual urine volume \> 250mL at baseline and \> 150mL after run-in (on bladder ultrasound)~* Continual leakage~* Urinary tract infection (growth of \> 100,000 colonies per ml of a urinary pathogen on urine culture). May be reconsidered after treatment and negative culture.~* Fecal impaction~* Poorly controlled diabetes (glycosylated hemoglobin \>9 within last 3 months)~* Hematuria on microscopic examination in the absence of infection~* Any unstable medical condition (particularly: decompensated congestive heart failure, malignant arrhythmias, unstable angina)~  -- Impaired mental status (\< 24 on Folstein's Mini-Mental State Exam)~* Narrow angle glaucoma~* Gastric retention (by medical history)~* Hypersensitivity to tamsulosin or oxybutynin~* Current use of anticholinergic agents for detrusor instability. May be reconsidered after 2-week wash-out.~* If on diuretic, dose has not been stable for at least three months~* Sleep apnea, unless surgically corrected

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Behavioral Training (Type: EXPERIMENTAL): Behavioral training using delayed voiding, urge suppression techniques, and pelvic floor muscle training
- Drug Therapy (Type: ACTIVE_COMPARATOR): Oxybutynin chloride, extended-release, individually-titrated, 5-30 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or women ≥ 18 and ≤ 80 years old~2. Subjects must be diagnosed with rheumatoid arthritis for at least 3 months before baseline~3. Active RA defined as ≥ 6 swollen joints and ≥ 6 tender joints at screening and baseline~4. Subjects must be taking MTX for ≥ 12 consecutive weeks and on a stable dose of 7.5 to 25 mg/week for \> 8 weeks prior to receiving the study drug and be willing to remain on stable dose throughout the study~5. Subject has no known history of active tuberculosis~Exclusion Criteria:~1. Class IV RA, Felty's syndrome or history of prosthetic or native joint infection~2. Major chronic inflammatory disease or connective tissue disease other than RA, with the exception of secondary Sjögren's syndrome~3. Prior use of 2 or more biologic therapies for RA~4. Previous receipt of HUMIRA® (adalimumab) or a biosimilar of adalimumab~5. Ongoing use of prohibited treatments~Other Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ABP 501 (Type: EXPERIMENTAL): Participants received ABP 501 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
- Adalimumab (Type: ACTIVE_COMPARATOR): Participants received adalimumab 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented compensated chronic hepatitis B defined by clinical history compatible with compensated chronic hepatitis B~* Detectable serum HBsAg at the Screening visit~Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Patient is pregnant or breastfeeding.~* Patient is coinfected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV~* Patient previously received lamivudine, adefovir dipivoxil, or an investigational anti-hepatitis B virus (HBV) nucleoside or nucleotide analog at any time~* Patient has received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Empowerment Self-Defense Training for the Prevention of Victimization of Transgender Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Transgender women (i.e., male assigned at birth, currently identified on the transfeminine spectrum)~* Between the ages of 18 and 65.~Exclusion Criteria:~* Cisgender men and women~* Transgender men

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Empowerment Self-Defense Training- Pre-Post Single Arm Design Pilot Trial (Type: OTHER): Refinement and assessment of the feasibility and acceptability of the Empowerment Self-Defense curriculum will occur in Phase 2 through the delivery of the tailored ESD curriculum to 3 groups of 16 TW.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ①Patients must have received radiation therapy for histologically confirmed nasopharyngeal carcinoma.~  * Prior irradiation \>/= 6 months prior to study entry.~    * Radiographic evidence to support the diagnosis of radiation-induced temporal lobe necrosis without tumor recurrence(15).~      * Age\>/= 18 years.~        * No evidence of very high intracranial pressure that suggests brain hernia and need surgery.~          * Fertile women who are willing to take contraception during the trial.~            * Routine laboratory studies with bilirubin \</=2 \* upper limits of normal (ULN), aspartate aminotransferase (AST or SGOT) \< 2 \* ULN, creatinine \<1.5 \* ULN, red-cell count \>/= 4,000 per cubic millimeter; white-cell count \>/=1500 per cubic millimeter, platelets \>/= 75,000 per cubic millimeter; Hb \>/=9.0. prothrombin time(PT), activated partial thromboplastin time(APTT),international normalized ratio(INR) in a normal range.~              * Ability to understand and willingness to sign a written informed consent document.~Exclusion Criteria:~* ①Tumor recurrence or metastases.~  * Diseases of central nervous system, such as cerebral vascular events, inflammatory, degenerative disease, and significant cardiovascular diseases.~    * Severe systemic diseases.~      * History of anaphylactic response to edaravone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edaravone group (Type: EXPERIMENTAL): Edaravone was used at a dose of 30mg,intravenously, twice per day, for 14 days. All patients also received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
- Control group (Type: EXPERIMENTAL): All patients in this group received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Patient with follicular lymphoma grade 1 - 2~* Refractory to rituximab given as monotherapy or in combination with any chemotherapy or to rituximab given as maintenance treatment following R-chemo, defined as:~* failure to achieve at least PR to rituximab given as monotherapy or in combination with any chemotherapy; or,~* disease progression while on rituximab (either given as monotherapy or in combination with any chemotherapy or during rituximab maintenance treatment following R-chemo); or,~* disease progression in responders within 6 months of the last dose of rituximab (either given as monotherapy or in combination with any chemotherapy or after rituximab maintenance treatment schedule following R-chemo)~* Tumor verified to be CD20+ positive from excisional lymph node biopsy~* CT scan in screening phase (based on local evaluation) showing:~* 2 or more clearly demarcated lesions with a largest diameter ≥ 1.5 cm, or~* 1 clearly demarcated lesion with a largest diameter ≥ 2,0 cm~* ECOG Performance Status of 0, 1, or 2~* Age ≥ 18 years~* Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out~Exclusion Criteria~* Previous autologous stem cell transplantation within 6 months~* Previous allogeneic stem cell transplantation~* More than 1 previous radio immunotherapy regimen~* Received radio immunotherapy within 3 months~* Received any Anti-cancer treatment within 4 weeks~* Received monoclonal antibodies, other than rituximab within 3 months~* Patients previously treated with anti-CD20 monoclonal antibodies, other than rituximab~* Life expectancy less than 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete